PepEvolutionKisspeptin-10
A reproductive-axis research peptide with a clean human safety signal but only early-phase trial evidence.
Verdict — C · Emerging / Mixed
A mechanistically elegant reproductive-axis peptide with genuinely clean early human data — but the evidence is still early-phase and sourcing is unverified. Interesting and comparatively low-risk for the experienced, not a settled buy.
Overview
Kisspeptin-10 is a fragment of the KISS1-gene product that stimulates GnRH release and sits upstream of the entire reproductive hormone axis. It has been studied in a credible series of early-phase human trials (notably from Imperial College, London) for hypothalamic amenorrhoea, IVF triggering and sexual-response research, with a reassuring short-acting safety profile. Evidence remains early-phase and the compound is not approved; gray-market availability exists but COA verification is the limiting factor.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.